CG Oncology (NASDAQ:CGON) Issues Quarterly Earnings Results

CG Oncology (NASDAQ:CGON) released its earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.14, Zacks reports. The company had revenue of $0.11 million during the quarter.

CG Oncology Trading Up 1.2 %

Shares of NASDAQ:CGON traded up $0.39 during midday trading on Friday, hitting $33.63. The company’s stock had a trading volume of 253,842 shares, compared to its average volume of 654,947. The stock’s 50 day simple moving average is $33.45 and its 200 day simple moving average is $36.47. CG Oncology has a fifty-two week low of $25.77 and a fifty-two week high of $50.23.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on CGON shares. The Goldman Sachs Group raised shares of CG Oncology from a “neutral” rating to a “buy” rating and upped their price target for the stock from $43.00 to $50.00 in a research note on Monday, May 13th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of CG Oncology in a research note on Tuesday, May 28th. Bank of America assumed coverage on CG Oncology in a research note on Friday, June 28th. They issued a “buy” rating and a $65.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $75.00 price target on shares of CG Oncology in a report on Thursday, May 2nd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $64.00.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.